Eicosanoid synthesis modulation

Eicosanoid synthesis modulation refers to the pharmacological or physiological regulation of the pathways responsible for generating eicosanoids, a family of bioactive lipid mediators derived mainly from arachidonic acid. Key enzymes in these pathways—cyclooxygenases (COX-1, COX-2), lipoxygenases (LOX), and cytochrome P450 epoxygenases—produce a range of molecules such as prostaglandins, thromboxanes, leukotrienes, and epoxyeicosatrienoic acids. Targeting these enzymes alters levels of specific eicosanoids, thereby affecting inflammation, pain, vascular tone, and immune responses. Therapeutic modulation of eicosanoid synthesis is achieved by drugs such as NSAIDs, COX-2 inhibitors, and leukotriene modifiers[1][2][4][7][8]. Because these pathways involve multiple molecular targets, “eicosanoid synthesis modulation” does not correspond to a single protein or receptor, but to the broader regulatory process impacting several druggable targets and enzymes.

Other names

Eicosanoid pathway modulationEicosanoid biosynthesis regulationEicosanoid pathway

Inhibition of cyclooxygenase (COX) enzymes; Inhibition of lipoxygenase (LOX) enzymes; Inhibition of cytochrome P450 epoxygenase; Inhibition of phospholipase A2 (PLA2)